Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework

Clinical Trials

Volumn 16, Issue 2, 2019, Pages 132-141

  Blenkinsop, Alexandra ^a   Parmar, Mahesh KB ^a   Choodari Oskooei, Babak ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

efficacy stopping boundary; familywise error rate; lack of benefit boundary; Multi arm; multi arm multi stage; multi stage

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SIMULATION; BIOASSAY; COMPUTER SIMULATION; METHODOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICAL BIAS; TIME FACTOR;

BIAS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TIME FACTORS;

EID: 85060727441     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774518823551     Document Type: Article

References (25)

1. Royston P, Parmar MK, Qian W., Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med 2003; 22(14): 2239–2256.
2. Royston P, Barthel FM, Parmar MK. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials 2011; 12(1): 81.
3. Parmar MK, Barthel FM, Sydes M. Speeding up the evaluation of new agents in cancer. J Natl Cancer I 2008; 100(17): 1204–1214.
4. Parmar MK, Sydes MR, Cafferty FH. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials 2017; 14(5): 451–461.
5. Haybittle J., Repeated assessment of results in clinical trials of cancer treatment. Brit J Radiol 1971; 44: 793–797.
6. O’Brien PC, Fleming TR., A multiple testing procedure for clinical trials. Biometrics 1979; 35(3): 549–556.
7. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70(3): 659–663.
8. Montori VM, Devereaux PJ, Adhikari NK. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294(17): 2203–2209.
9. Armitage P, McPherson CK, Rowe BC., Repeated significance tests on accumulating data. J R Stat Soc 1969; 132(2): 235–244.
10. Wason JMS, Stecher L, Mander AP., Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?Trials2014; 15(1): 364.
11. Barthel FMS, Royston P, Parmar M., A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome. Stata J 2009; 9(4): 505–523.
12. Bratton DJ, Choodari-Oskooei B, Royston P., A menu-driven facility for sample-size calculation in multiarm, multistage randomized controlled trials with time-to-event outcomes: update. Stata J 2015; 15(2): 350–368.
13. Sydes MR, Parmar MK, Mason MD. Flexible trial design in practice – stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 2012; 13(1): 168.
14. Crouch LA, Dodd LE, Proschan MA., Controlling the family-wise error rate in multi-arm, multi-stage trials. Clin Trials 2017; 14(3): 237–245.
15. Magirr D, Jaki T, Whitehead J., A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. Biometrika 2012; 99(2): 494–501.
16. Ghosh P, Liu L, Senchaudhuri P. Design and monitoring of multi-arm multi-stage clinical trials. Biometrics 2017; 73(4): 1289–1299.
17. Bratton DJ, Parmar MKB, Phillips PPJ. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes. Trials 2016; 17(1): 309.
18. Ramsey PH., Power differences between pairwise multiple comparisons. J Am Stat Assoc 1978; 73(363): 479–485.
19. Horn M, Vollandt R., Sample sizes for comparisons of k treatments with a control based on different definitions of the power. Biometrical J 1998; 40(5): 589–612.
20. Urach S, Posch M., Multi-arm group sequential designs with a simultaneous stopping rule. Stat Med 2016; 35(30): 5536–5550.
21. DeMets DL, Lan KKG. Interim analysis: the alpha spending function approach. Stat Med 1994; 13(13–14): 1341–1352.
22. Bookman MA, Brady MF, Mcguire WP. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009; 27(9): 1419–1426.
23. Wason J, Magirr D, Law M. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res 2016; 25(2): 716–727.
24. Choodari-Oskooei B, Parmar MK, Royston P. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome. Trials 2013; 14(1): 23.
25. Blenkinsop A, Choodari-Oskooei B. Multi-arm, multi-stage randomized controlled trials with stopping boundaries for efficacy and lack-of-benefit: an update to nstage. Stata J, Under Review.